|
1
|
Crosnier A, Abbara C, Cellier M, Lagarce L, Babin M, Bourneau-Martin D, Briet M. Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase ® the WHO Global Database of Individual Case Safety Reports. Cancers (Basel) 2021; 13:5907. [PMID: 34885014 PMCID: PMC8657199 DOI: 10.3390/cancers13235907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 11/12/2021] [Accepted: 11/19/2021] [Indexed: 01/22/2023] Open
Abstract
Kidney EGFR expression together with reported cases of glomerular diseases in the context of anti-EGFR drug administration raise concerns about the renal safety profile of these drugs. This issue is addressed in a case/non-case study carried out on VigiBase®, the WHO global database of individual case safety reports (ICRS). Disproportionality analysis of renal adverse effects related to the selected anti-EGFR drugs, erlotinib, gefitinib, afatinib, osimertinib, cetuximab and panitumumab, was assessed using the reporting odds ratio (ROR). Nine hundred and eighty-nine ICRSs were included. A signal of disproportionate reporting (SDR) was found for afatinib (ROR = 2.70; 95% CI [2.22-3.29]) and erlotinib (ROR = 1.73; 95% CI [1.46-2.04]) with acute kidney injury, and for afatinib (ROR = 2.41; 95% CI [1.78-3.27]), cetuximab (ROR = 1.42; 95% CI [1.14-1.78]) and erlotinib (ROR = 2.23; 95% CI [1.80-2.77]) with renal failure. The preferred term "diarrhoea" was frequently reported in the included cases. An SDR was found for erlotinib with haemolytic and uremic syndrome (ROR = 4.01; 95% CI [1.80-8.94]) and thrombotic microangiopathy (ROR = 4.94; 95% CI [2.80-8.72]). No SDR was seen for glomerular or tubule-interstitial diseases. This study showed that the anti-EGFR drug renal toxicity is mainly related to renal failure in the context of digestive toxicity.
Collapse
Affiliation(s)
- Alexandre Crosnier
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
- Département de Médecine, Faculté de Médecine d’Angers, Université d’Angers, 49035 Angers, France
| | - Chadi Abbara
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
| | - Morgane Cellier
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
| | - Laurence Lagarce
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
| | - Marina Babin
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
| | - Delphine Bourneau-Martin
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
| | - Marie Briet
- Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France; (A.C.); (C.A.); (M.C.); (L.L.); (M.B.); (D.B.-M.)
- Département de Médecine, Faculté de Médecine d’Angers, Université d’Angers, 49035 Angers, France
- Research Institute MitoVasc, UMR CNRS 6214 INSERM 1083, University of Angers, 49100 Angers, France
| |
Collapse
|